remdesivir - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID 19 hospitalized
	COVID-19 mild to moderate
remdesivir	GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ...

1 studies excluded by filtering options 2

5209

SIMPLE (Grein), 0

2

30

0

excluded

not a RCT

risk of bias not avaialble